DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring With EU-MDR Certification
DentalMonitoring is proud to announce that the DentalMonitoring Software is now certified under the European Union Medical Device Regulation 2017/745 (EU MDR) and fulfills the requirements for CE marking as a class IIa medical device. European Medical Device Regulation 2017/745 (EU MDR) replaces the previous Medical Device Directive 93/42/EEC (MDD). EU MDR sets more rigorous requirements for clinical evaluation, risk management, post-market surveillance, and data collection on medical devices.(1) This landmark achievement underscores DentalMonitoring's commitment to advancing dental care through cutting-edge technology and rigorous regulatory compliance. Achieving this certification four years ahead of the deadline demonstrates DentalMonitoring's commitment to positioning itself as an innovative, serious, efficient, and safe player in the medical field.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614842101/en/
DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring with EU-MDR Certification (Graphic: Business Wire)
DentalMonitoring is a medical device software using image processing algorithms to analyze high-quality intraoral scans taken by patients using the DM App, a smartphone, and proprietary hardware. The software allows healthcare professionals to remotely monitor dental treatments, orthodontic treatments, oral health, and treatment progress. The medical device software aids clinicians in diagnosis and treatment planning through weekly clinical updates.
With DentalMonitoring, clinicians enjoy an elevated level of insight into treatment progress while patients enjoy increased convenience. Automated notifications and in-app communication with practice staff increase patient accountability and enhance communication between patients and healthcare providers. This level of connection promotes patient compliance with orthodontic treatment requirements.
Philippe Salah, CEO and co-founder of DentalMonitoring, said, “I’m incredibly proud that DentalMonitoring has achieved EU MDR certification along with US/FDA DeNovo 510k clearance. These achievements celebrate our relentless pursuit of innovation and excellence in oral care. Our AI-powered solutions are now recognized at the highest regulatory levels, enabling us to expand our reach and impact more lives with advanced dental technology.”
“The requirements of EU MDR are much more rigorous, sometimes compelling medical device manufacturers to rethink their European commercial strategy. We are very pleased to have successfully met these requirements four years before the deadline set by the European Union. EU MDR Certification is a significant milestone that underscores DentalMonitoring's commitment to quality, efficiency and patient safety,” said Arnaud Berthier, Director of Regulatory, Quality and Clinical Affairs at DentalMonitoring.
About DentalMonitoring:
DentalMonitoring is transforming orthodontic care globally through our advanced AI-driven platform. Our mission is to empower orthodontic practitioners with precise, real-time treatment monitoring and decision-making tools. By enhancing the connection between clinicians and patients, we make it possible to optimize treatment outcomes and ensure high-quality, efficient, and personalized orthodontic experiences. Visit www.DentalMonitoring.com and follow DentalMonitoring on LinkedIn.
(1) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240614842101/en/
Contacts
Celine Cendras-White
Head of Marketing Communication
public-relations@dental-monitoring.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries and Veolia Partner to Redefine Industrial Water Use at the Pacifico Mexinol Project in Mexico13.1.2025 09:24:00 CET | Press Release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, and Veolia Water Technologies & Solutions, world leader in water technology, have signed an agreement to explore the provision of advanced industrial water technology for the Pacifico Mexinol project in Sinaloa, Mexico. Expected to initiate operations in 2028, Pacifico Mexinol is poised to be the world’s largest standalone ultra-low carbon chemical production facility in the world, with an output of 6,145 metric tons of methanol (MT) per day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112655528/en/ The memorandum of understanding (MOU) outlines the collaboration between Transition Industries and Veolia to develop a purpose-driven water strategy for the Pacifico Mexinol project. Designed with Ahome Municipality’s Drinking Water and Sewage Board (JAPAMA), this strategy would make the Pacifico Mexinol site one
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer13.1.2025 09:00:00 CET | Press Release
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candidates, EGL-001 and EGL-003. “I am thrilled to join Egle Therapeutics and collaborate with a team renowned for its deep scientific expertise in regulatory T cells and its strong track record in developing innovative drug candidates for immunology and oncology,” said Christophe Quéva, Ph.D. “Egle is uniquely positioned to demonstrate the therapeutic potential of harnessing regulatory T cells for treating both cancer and autoimmune diseases.” “As we transition from a company with preclinical assets to a fully-fledged clinic
Avanzanite Bioscience Announces Appointment of Chief Technical Officer to Accelerate European Expansion and Drive Growth13.1.2025 07:00:00 CET | Press Release
Avanzanite Bioscience B.V., a leading commercial-stage specialty pharmaceutical company committed to bringing ground-breaking medicines for rare diseases to market, announced today the appointment of Jason Cameron as Chief Technical Officer (CTO). This move marks a significant step in Avanzanite’s mission to accelerate growth, expand its presence in Europe, and advance the company’s next phase of international partnerships and product launches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112229499/en/ Jason Cameron, Chief Technical Officer, Avanzanite Bioscience (Photo: Business Wire) As CTO, Cameron will initially focus on the strategic expansion of Avanzanite’s footprint into 26 European countries, driving revenue growth for the current portfolio while also preparing for key new partnerships expected to materialize in 2025. With over 25 years of experience in pharmaceutical operations, Mr. Cameron brings unparalleled
Dubai Culture Launches ‘Creative Dubai – Navigating Tomorrow’s Creative Landscape’ Report13.1.2025 07:00:00 CET | Press Release
Dubai Culture and Arts Authority (Dubai Culture) has launched the ‘Creative Dubai: Navigating Tomorrow’s Creative Landscape’ report developed in collaboration with DinarStandard, a privately owned growth strategy research and advisory firm empowering organisations for responsible global impact. The report highlights Dubai’s achievements in the cultural and creative industries, the key factors contributing to the city’s cultural vision, and significant data tracking the sector’s transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112169940/en/ Key Highlights of Creative Economy Figures and FDI in Dubai’s Cultural and Creative Industries (Graphic: AETOSWire) The report provides a comprehensive overview of the creative sector, which serves as a significant global economic force, representing 6.1% of the global economy with a total value of US$4.3 trillion. The report also shows that the UAE has the largest creativ
PQ slutför förvärvet av Sibelcos specialiserade silikatverksamhet i Sverige13.1.2025 06:00:00 CET | Pressmeddelande
PQ (www.pqcorp.com), en ledande global producent av silikater, silika och derivatprodukter, meddelade att de har slutfört förvärvet av Sibelco-koncernens specialiserade silikatverksamhet som för närvarande bedrivs vid Lödöse-anläggningen i Sverige. ”PQ är glada över att ha slutfört denna transaktion med Sibelco och vi ser fram emot att börja erbjuda våra produkter och tjänster till nya kunder i regionen,” sade Al Beninati, VD för PQ. ”Vårt robusta europeiska nätverk och expertis inom specialiserade silikater kommer att möjliggöra för våra nya kunder att uppnå tillväxt i Norden.” Om PQ Med huvudkontor i Malvern, Pennsylvania är PQ en ledande global leverantör av silikater, silika och derivatprodukter. PQs produkter finns i en mängd olika industrier och många aspekter av vardagen, från dekorativa färger till grön cement, från rent dricksvatten till gröna däck och från tandkräm till att hjälpa till vid produktion av biobränslen och öl. Stödd av 1 500 anställda på 30 anläggningar i 13 länd
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom